AVTR vs. BIIB: Avantor vs. Biogen Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Biogen (BIIB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Biogen (BIIB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while BIIB is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and Biogen (BIIB)
Profile Item	AVTR	BIIB
Name	Avantor, Inc.	Biogen Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.48 billion USD	36.71 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	September 17, 1991
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

BIIB

GSPC

Avantor (AVTR) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Biogen (BIIB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Biogen (BIIB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Total Return (1Y)	36.41%	65.44%
Total Return (3Y, Annualized)	-5.02%	4.62%
Total Return (5Y, Annualized)	-16.62%	-0.96%

Risk Profile

Drawdown History

AVTR

BIIB

GSPC

Avantor (AVTR) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Biogen (BIIB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Volatility (1Y, Annualized)	43.39%	34.58%
Beta (5Y)	0.94	0.08
Max Drawdown (5Y)	-82.42%	-64.35%
Avg. Volume (3M)	8.56M	1.05M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and BIIB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Sharpe Ratio (1Y)	0.74	1.77
Sortino Ratio (1Y)	1.17	2.77

Profitability

ROE (TTM)

Both Avantor (AVTR) at 5.91% and Biogen (BIIB) at 1.87% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Biogen (BIIB) at 3.38%, which keeps about the industry-typical share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Biogen (BIIB) at 24.12% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
ROE (TTM)	5.91%	1.87%
ROA (TTM)	2.83%	4.94%
Net Margin (TTM)	5.08%	3.38%
Operating Margin (TTM)	8.19%	24.12%
Gross Margin (TTM)	31.59%	75.77%

Growth

Revenue Growth

Biogen (BIIB) at 2.22% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Biogen (BIIB) at -21.38% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Revenue Growth (YoY)	-3.41%	2.22%
Revenue Growth (3Y CAGR)	-4.46%	-0.94%
EPS Growth (YoY)	-175.00%	-21.38%
EPS Growth (3Y CAGR)	--	-25.04%

Financial Strength

Current Ratio (MRQ)

Both Avantor (AVTR) at 1.89 and Biogen (BIIB) at 1.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Avantor (AVTR) at 0.63 and Biogen (BIIB) at 0.41 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Current Ratio (MRQ)	1.89	1.95
Debt / Equity (MRQ)	0.63	0.41
Net Debt / EBITDA	3.40	1.97

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor Biogen (BIIB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor Biogen (BIIB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Avantor (AVTR) at 1.80 and Biogen (BIIB) at 1.94 are valued close to their industries’ norm against book — neither stands out from peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Biogen (BIIB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Biogen (BIIB)
Metric	AVTR	BIIB
P/E Ratio (TTM)	30.94	107.51
P/S Ratio (TTM)	1.58	3.57
P/B Ratio (MRQ)	1.80	1.94
Free Cash Flow Yield (TTM)	4.21%	2.20%